Related Experiment Videos
[Changes of genomic density polymorphism and quantitative expression of complement receptor type 1 in patients with
1Department of Immunology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China.
Insights
Patients with liver diseases show reduced levels of complement receptor type 1 (CR1) on erythrocytes, indicating defective CR1 expression is acquired. This quantitative change is crucial for evaluating liver disease progression.
Area of Science:
- Immunology
- Hepatology
- Genetics
Context:
- Liver diseases are associated with complex immunological alterations.
- Complement receptor type 1 (CR1) plays a role in immune regulation.
- Erythrocytes express CR1, influencing immune responses.
Purpose:
- To investigate genomic density polymorphism of CR1.
- To quantify CR1 expression on erythrocytes in liver disease patients.
- To correlate CR1 changes with liver disease severity.
Summary:
- Genomic density polymorphism of CR1 did not differ significantly between liver disease patients and healthy individuals.
- Quantitative expression of erythrocytic CR1 was significantly lower in liver disease patients compared to controls.
- CR1 expression decreased progressively from compensated to decompensated cirrhosis.
Impact:
- Defective CR1 expression in liver disease is likely acquired, not solely genetic.
- Quantitative CR1 analysis is important for assessing liver disease development.
- Findings suggest potential therapeutic targets related to CR1 modulation.
Objective:
To study the changes of genomic density polymorphism and quantitative expression of complement receptor type 1 (CR1) on erythrocytes in patients with liver diseases.
Methods:
Polymerase chain reaction (PCR) and Hind III restriction enzyme digestion and the quantitative assay of erythrocytic CR1 were used.
Results:
The spot mutation rate (25.0% approximately 30.3%) of erythrocyte CR1 density gene in patients with liver diseases was not significantly different with that of healthy individuals (28.0%). The amount of erythrocytic CR1 in patients with liver diseases, except for those with normal liver function, was significantly lower than that of healthy individuals (t=10.44, P<0.0001). The quantitative expression of erythrocytic CR1 in decompensated cirrhosis was obviously lower than that of compensated cirrhosis (t=2.21, P<0.05).
Conclusion:
Defective expression of CR1 in liver diseases is acquired through central and/or peripheral mechanisms. It is very important to study the quantitative expression in the evaluation of the development of liver diseases.